Comparison Table

Please rotate your device for details

  TruSeq Targeted RNA Expression TruSight RNA Pan-Cancer Panel TruSight RNA Fusion Panel
Description Customizable mid- to high-plex gene expression analysis with user-defined panels of 12-1000 assays. Comprehensive assessment of cancer-related RNA transcripts enabling detection of gene fusions, variants, and gene expression changes in all cancer types. Gene fusion detection with known and novel partners in 507 fusion associated genes. Simplified analysis solution reports all detected fusions.
Design
  • Custom Panel
  • Neurodegeneration Panel
  • Apoptosis Panel
  • NFkB Panel
  • Cardio Toxicity Panel
  • Stem Cell Panel
  • Cell Cycle Panel
  • TP53 Panel
  • Cytochrome p450 Panel
  • WNT Pathway Panel
  • Hedgehog Panel
 Pan-Cancer Panel with 1,385 targeted genes and 21,043 targeted exonic regions. Includes 507 genes involved in cancer gene fusions. Gene fusion panel targeting 507 cancer-associated fusion genes and 7690 exons.
Method Amplicon Enrichment Enrichment
Input (total RNA) 50 ng for high quality RNA
≥ 200 ng for degraded/FFPE RNA		 10 ng for high quality RNA
20–100 ng for FFPE RNA		 10 ng for high quality RNA
20–100 ng for FFPE RNA
FFPE Compatible Yes Yes Yes
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2026 Illumina, Inc. All rights reserved.